4+1 the right balance in Parkinson's disease



Presentation
Madopar contains a combination of levodopa and the decarboxylase inhibitor benserazide in the ratio of 4:1. Madopar 62.5 capsules containing 50mg levodopa and 12.5mg benserazide hydrochloride (equivalent to 12.5mg of the base). Madopar 125 capsules containing 100mg levodopa and 25mg benserazide hydrochloride (equivalent to 25mg of the base). Madopar 250 capsules containing 200mg levodopa and 50mg benserazide hydrochloride (equivalent to 50mg of the base).

Indications
Parkinsonism – idiopathic, post-encephalitic.

Dosage
Dosage is variable and the data sheet should be consulted for full details. The effective daily dose usually lies between four and eight capsules of Madopar 125 (two to four capsules of Madopar 250) daily in divided doses; most patients requiring no more than six capsules of Madopar 125 daily. In some elderly patients initial treatment with one capsule of Madopar 62.5 once or twice daily, increasing by one capsule every third or fourth day may suffice. Patients who experience fluctuations in response may also benefit from administration of smaller more frequent doses using Madopar 62.5.

Contra-indications
Narrow-angle glaucoma, severe psychoneuroses or psychoses. It should not be given in conjunction with monoamine oxidase inhibitors or within two weeks of their withdrawal, to patients under 25 years of age, to pregnant women, or to patients who have a history of, or who may be suffering from, a malignant melanoma.

Precautions
Drugs which interfere with central amine mechanisms should be avoided. Endocrine, renal, pulmonary or cardiovascular disease, hepatic disorder, peptic ulcer, osteoporosis, sympathomimetic drugs, antihypertensive drugs. Patients who improve on Madopar therapy should be advised to resume normal activities gradually as rapid mobilisation may increase the risk of injury.

Side-effects
Nausea and vomiting, cardiovascular disturbances, psychiatric disturbances, involuntary movements.

Packings
Madopar 62.5 capsules, Madopar 125 capsules and Madopar 250 capsules in packings of 100.

Licence Numbers
0031/0125 (Madopar 62.5 capsules); 0031/0073 (Madopar 125 capsules); 0031/0074 (Madopar 250 capsules).

Basic NHS Cost
Madopar capsules 62.5
£5.41 per 100
Madopar capsules 125
£9.76 per 100
Madopar capsules 250
£17.47 per 100

ROCHE

Roche Products Limited
PO Box 8
Welwyn Garden City
Hertfordshire AL7 3AY

Madopar is a trade mark.
(522210/283

the original 4+1 combination in three dosage forms, and

Macarthys

MACROM NEUROSURGICAL PATTIES

British Made
100% Cotton
Fast High Absorption
Non Toxic
Soft Texture
Plain or X-Ray Opaque
Range of Sizes

Double Wrapped in See Through Envelopes
Ready For Immediate Sterilisation

FINE SURGICAL INSTRUMENTS *British Made*

Macarthys



Cloward Laminectomy Disc Punch
⅔rd scale

A new era in the treatment of Parkinson's disease has begun. Eldepryl is the new, selective inhibitor of the enzyme responsible for dopamine breakdown in the brain. Used in conjunction with L-dopa or L-dopa/decarboxylase inhibitor combinations, Eldepryl provides the next vital step in treatment of all stages of Parkinson's disease – dopamine conservation.

The patient benefits of Eldepryl are substantial – daily L-dopa intake can be immediately cut by 20% in most cases [1,2] reducing unwanted side-effects and extending the useful life of L-dopa. With a notable lack of adverse effects, Eldepryl significantly reduces akinesia, smoothes out "on-off" effects, and has been shown in a recent long-term study [3] to significantly prolong the evolution of the disease.
With Eldepryl, there is no complicated dosage regime to remember, simply one tablet daily, together with a 20% reduction of L-dopa on the first day of treatment, is usually all that is required.

PRESCRIBING INFORMATION
Presentation: White, scored, uncoated tablets 6 mm dia... containing 5 mg selegiline hydrochloride. **Indications:** El... indicated for the treatment of Parkinson's disease, or symp... Parkinsonism, which is being treated with levodopa alon... levodopa and a peripheral decarboxylase inhibitor. El... conjunction with levodopa treatment is particularly ... patients who, during maximal levod... treatment... symptoms or other dyskinesias. **D...** conjunction with established levod... Eldepryl is 5 mg (1 tablet) in the mo... severe, e.g. on-off symptoms, and... with 1 tablet Eldepryl daily, the do... to 10 mg (2 tablets) in the morning. **WARNINGS ETC.: Contra-indic...** contra-indications for the use of El... levodopa therapy. **Warnings:** Bec... the effects of levodopa, the side effects... emphasised. When Eldepryl is added to ... levodopa treatment, involuntary movements and agitation may occur. Levodopa treatment can be reduced by an average of ... treatment. When an optimal ... the side effects of the ... dopa alone. **Side Effects:** ... reported as isolated ... ment. Confusion ... **Category:** P... **...sic NHS Co...** ... **...e Reactio...** of 100 tablets, £35.10 ... uced product, any suspected adverse reactions ... orted to the Committee on Safety of Medicines. ... yellow card. **Date of Preparation:** April 1983. ...ransmission, 1976;4...45-251. **2.** Ibid, 1976;36:303- ...Probl... ...macopsychiat., 1983;19:170-176 (Karger, Basel).

ADD Eldepryl®

Selegiline hydrochloride

Whenever you prescribe L-dopa

Further information is available on request from: **Britannia Pharmaceuticals Limited, Hamilton House, 87-89 Bell Street, Reigate, Surrey RH2 7YZ.**


MODE
POWER
AUTO-
START
Coa-Comp
ISBAB





The body provides invaluable information in its thermal distribution.

The Flexi-Therm Thermography System converts this into a temperature-calibrated visual image to reveal the characteristic heat profile which many disorders present.

Analysis of this image can provide identification, localisation and differentiation in the following disorders:

spinal nerve root syndromes, ulnar and median nerve entrapments, thoracic outlet syndrome, peripheral nerve injuries with sympathetic dysfunction, sensory nerve deficit, myofascial pain syndromes, cerebrovascular disorders due to carotid artery narrowing, and peripheral vascular disorders.

Flexi-Therm is highly effective for monitoring the success of subsequent treatment, bringing objectivity into a subjective field.

All this at a price which keeps Flexi-Therm well within the scope of everyday clinical use.









Published by British Medical Association, Tavistock Square, London WC1H 9JR
and printed in England by Eyre & Spottiswoode Ltd, Thanet Press, Margate, Kent